Although lipoprotein(a) is believed to play a causal role in atherogenesis, there are no approved therapies to help lower it. The OCEAN(a) DOSE study examined a drug specifically designed to lower lipoprotein(a) through RNA interference.

In this interview, Michelle L. O'Donoghue MD, MPH and Nanette Kass Wenger MD, MACC discuss AHA Late-Breaker: OCEAN(a)-DOSE – Reduction of Lipoprotein(a) With Small Interfering RNA.

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL